Showing results (101-110 of 233) with videos related to

Sort By:
Pageof 24
The Journal of Clinical Investigation|July 15, 1996
The PAX2 tanscription factor is expressed in cystic and hyperproliferative dysplastic epithelia in human kidney malformationsP J Winyard, R A Risdon, V R Sams, et al.
The American Journal of Pathology|December 8, 2004
Dysmorphogenesis of kidney cortical peritubular capillaries in angiopoietin-2-deficient miceJolanta E Pitera, Adrian S Woolf, Nicholas W Gale, et al.
Nephron|January 1, 1989
Effects of physiological infusion of atrial natriuretic factor on healthy subjects and patients with the nephrotic syndromeA S Woolf, T L Lyon, B I Hoffbrand, et al.
The Journal of Pathology|May 19, 2018
Functional molecules in mesothelial-to-mesenchymal transition revealed by transcriptome analysesSara Namvar, Adrian S Woolf, Leo Ah Zeef, et al.
Journal of Tissue Engineering and Regenerative Medicine|August 4, 2015
Bridging the gap: functional healing of embryonic small intestine ex vivoRiccardo Coletta, Neil A Roberts, Francesca Oltrabella, et al.
Postgraduate Medical Journal|June 1, 1989
The effects of low dose intravenous 99-126 atrial natriuretic factor infusion in patients with chronic renal failureA S Woolf, M A Mansell, B I Hoffbrand, et al.
The American Journal of Pathology|November 25, 2003
Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alphaHai-Tao Yuan, Xiao-Zhong Li, Jolanta E Pitera, et al.
BJU International|July 13, 2006
Vascular endothelial growth factor stimulates embryonic urinary bladder development in organ cultureBerk Burgu, Liam S McCarthy, Vanita Shah, et al.
The American Journal of Pathology|August 4, 2001
Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesionsE Pillebout, M Burtin, H T Yuan, et al.
Investigational New Drugs|January 1, 1985
A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancerJ C Allegra, T Woodcock, S Woolf, et al.
Pageof 24